$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2024 Q3 Form 10-Q Financial Statement

#000141057824002000 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.003M
YoY Change -26.09%
% of Gross Profit
Research & Development $1.045M
YoY Change -68.62%
% of Gross Profit
Depreciation & Amortization $59.00K
YoY Change -9.23%
% of Gross Profit
Operating Expenses $1.045M
YoY Change -68.62%
Operating Profit -$3.048M
YoY Change -49.49%
Interest Expense $394.0K
YoY Change -92.01%
% of Operating Profit
Other Income/Expense, Net -$54.00K
YoY Change -55.0%
Pretax Income -$2.708M
YoY Change 120.16%
Income Tax
% Of Pretax Income
Net Earnings -$2.708M
YoY Change 120.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$0.51
COMMON SHARES
Basic Shares Outstanding 79.73M
Diluted Shares Outstanding 5.310M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $168.0K
YoY Change -88.17%
Cash & Equivalents $168.0K
Short-Term Investments
Other Short-Term Assets $156.0K
YoY Change 160.0%
Inventory
Prepaid Expenses
Receivables $40.00K
Other Receivables $0.00
Total Short-Term Assets $364.0K
YoY Change -76.35%
LONG-TERM ASSETS
Property, Plant & Equipment $499.0K
YoY Change -33.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.661M
YoY Change -59.91%
Total Long-Term Assets $1.661M
YoY Change -59.91%
TOTAL ASSETS
Total Short-Term Assets $364.0K
Total Long-Term Assets $1.661M
Total Assets $2.025M
YoY Change -64.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.603M
YoY Change 17.24%
Accrued Expenses $865.0K
YoY Change 1273.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.082M
YoY Change 12.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.000M
YoY Change -48.45%
Total Long-Term Liabilities $1.000M
YoY Change -48.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.082M
Total Long-Term Liabilities $1.000M
Total Liabilities $8.082M
YoY Change -2.2%
SHAREHOLDERS EQUITY
Retained Earnings -$223.7M
YoY Change 7.02%
Common Stock $217.7M
YoY Change 5.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.057M
YoY Change
Total Liabilities & Shareholders Equity $2.025M
YoY Change -64.36%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.708M
YoY Change 120.88%
Depreciation, Depletion And Amortization $59.00K
YoY Change -9.23%
Cash From Operating Activities -$3.299M
YoY Change -48.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.299M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -3.299M
YoY Change -588.02%
FREE CASH FLOW
Cash From Operating Activities -$3.299M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2683700
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2950121
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223663000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5703426
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1300000
CY2024Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
40000
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
51000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
156000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
548000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
364000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1899000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
181000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
185000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
959000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
499000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
686000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2309000
CY2024Q3 us-gaap Assets
Assets
2025000
CY2023Q4 us-gaap Assets
Assets
4208000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4603000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4954000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
865000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1240000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
570000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
603000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1044000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1003000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7082000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7800000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
271000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672000
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
729000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
594000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1000000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1266000
CY2024Q3 us-gaap Liabilities
Liabilities
8082000
CY2023Q4 us-gaap Liabilities
Liabilities
9066000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
14000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5309796
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5309796
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4032614
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4032614
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
217708000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210258000
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223663000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215013000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6057000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2025000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4208000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2928000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9048000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1045000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3330000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5576000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7587000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2003000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2705000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8504000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16635000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3048000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6035000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
11000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-91000
CY2024Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
54000
CY2023Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
121000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
135000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-394000
us-gaap Net Income Loss
NetIncomeLoss
-8650000
us-gaap Net Income Loss
NetIncomeLoss
-11614000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2708000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1226000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.35
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4793026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4793026
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2683700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2683700
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2683700
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5309796
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5309796
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2950121
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2950121
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000
CY2023Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
3230000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
988000
CY2023Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
5299000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5329000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3882000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
548000
CY2023Q3 bcli Issuance Of Shares For Private Placement Value
IssuanceOfSharesForPrivatePlacementValue
1978000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1226000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2582000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
170000
CY2024Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
2539000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3401000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5550000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
194000
CY2024Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
725000
CY2024Q2 bcli Issuance Of Shares For Private Placement Value
IssuanceOfSharesForPrivatePlacementValue
3645000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2541000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3527000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
178000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2708000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6057000
us-gaap Profit Loss
ProfitLoss
-8650000
us-gaap Profit Loss
ProfitLoss
-11614000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-2708000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1226000
us-gaap Depreciation
Depreciation
187000
us-gaap Depreciation
Depreciation
199000
CY2024Q3 us-gaap Depreciation
Depreciation
59000
CY2023Q3 us-gaap Depreciation
Depreciation
65000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
542000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1540000
CY2024Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
178000
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
548000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
23000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-183000
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
30000
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-58000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-403000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-4000
CY2024Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-149000
CY2023Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-345000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-351000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-298000
CY2024Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-737000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1264000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
135000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-394000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-334000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-60000
CY2024Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
124000
CY2023Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-58000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8045000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17173000
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3299000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6409000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2015000
CY2023Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1997000
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
bcli Proceeds From At Market
ProceedsFromAtMarket
3264000
bcli Proceeds From At Market
ProceedsFromAtMarket
8529000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3645000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7097000
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7097000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6909000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15626000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7097000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1136000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
450000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3299000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
676000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1485000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3648000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
349000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1222000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
349000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1222000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
349000
us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:43.2pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">D.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Use of estimates</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 61.2pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
959000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
841000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1275000
us-gaap Lease Cost
LeaseCost
324000
us-gaap Lease Cost
LeaseCost
619000
us-gaap Operating Lease Payments
OperatingLeasePayments
496000
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000
bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
492000
bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
1209000
bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
28000
bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
-293000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0850
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
149000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
563000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
185000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
897000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
56000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
841000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
178000000
us-gaap Share Based Compensation
ShareBasedCompensation
542000
us-gaap Share Based Compensation
ShareBasedCompensation
1540000
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q2 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q2 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
2
CY2024Q3 bcli Listed Securities Market Value
ListedSecuritiesMarketValue
35000000
CY2024Q3 bcli Listed Securities Market Value
ListedSecuritiesMarketValue
35000000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 bcli Non Rule10b51 Arrangement Modified Flag
NonRule10b51ArrangementModifiedFlag
false
CY2024Q3 bcli Rule10b51 Arrangement Modified Flag
Rule10b51ArrangementModifiedFlag
false

Files In Submission

Name View Source Status
0001410578-24-002000-index-headers.html Edgar Link pending
0001410578-24-002000-index.html Edgar Link pending
0001410578-24-002000.txt Edgar Link pending
0001410578-24-002000-xbrl.zip Edgar Link pending
bcli-20240930.xsd Edgar Link pending
bcli-20240930x10q.htm Edgar Link pending
bcli-20240930xex31d1.htm Edgar Link pending
bcli-20240930xex31d2.htm Edgar Link pending
bcli-20240930xex32d1.htm Edgar Link pending
bcli-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
bcli-20240930_cal.xml Edgar Link unprocessable
bcli-20240930_def.xml Edgar Link unprocessable
bcli-20240930_lab.xml Edgar Link unprocessable
bcli-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20240930x10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending